The efficacy of mobilizing peripheral blood progenitor cells (PBPC) with continuous intravenous (c.i.v.) administration of rhG-CSF was randomly compared to subcutaneous (s.c.) administration, in 15 normal donors in each arm of the study for 6 days. The percentage and absolute numbers of CD34 þ cells in the c.i.v. and s.c. groups increased maximally at day 3 and 5, respectively, when compared with the steady-state (day 0) level. Peak CD34 þ cell levels were achieved on day 3 in the c.i.v. group, with more rapid results than in the s.c. group (49.3/ ll vs 35.9/ll, P ¼ 0.043). Plasma rhG-CSF levels declined progressively during mobilization in each group as the WBC increased. The serum level of rhG-CSF did not correlate with CD34 þ cell counts in the peripheral blood. Toxicity profiles in the c.i.v. and s.c. groups were similar. Each regimen was effective in successfully mobilizing the target CD34 cell number.
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Allogeneic peripheral blood progenitor cell (PBPC) transplantation from normal donors who have undergone mobilization with recombinant human granulocyte-colonystimulating factor (rhG-CSF) has produced durable engraftment and rapid hematopoietic reconstitution after myeloablative and nonmyeloablative conditioning regimens. Optimal doses and schedules of rhG-CSF have not yet been established. There are conflicting reports on whether a twice daily subcutaneous (s.c.) schedule of rhG-CSF is more effective than a once daily, 10 mg/kg dose of rhG-CSF. [1] [2] [3] High doses (ie, 20-24 mg/kg/day) of rhG-CSF have been reported to provide better yields than lower doses (ie, 10-12 mg/kg/d) of rhG-CSF. 4, 5 In addition, Watts et al 6 have reported a lack of correlation between serum rhG-CSF concentration achieved and peak progenitor cell counts. 6 Owing to the short elimination half-life of rhG-CSF (about 3À6 h), administration of s.c. rhG-CSF once or even twice daily might be suboptimal. [6] [7] [8] We previously investigated the efficacy in mobilizing PBPC with a continuous intravenous (c.i.v.) administration schedule. 9 In that study, 15 healthy donors were enrolled. rhG-CSF (10 mg/kg/day) was administered for 5 consecutive days by continuous 24-h intravenous infusion. Complete blood counts and CD34 þ cell levels were taken immediately before rhG-CSF administration (steady-state) and after 4, 8, 24, 48, 72, 96 , and 120 h of rhG-CSF administration. The percentage and absolute numbers of CD34 þ cells increased significantly after day 3 (0.5570.09%, 51.12724.83 Â 10 3 /ml) compared to the pre-mobilization level (0.0670.09%, 2.0375.69 Â 10 3 /ml). This was faster than with subcutaneous use. We have now conducted a prospective randomized study on mobilization of CD34 þ cells, comparing c.i.v. vs s.c. administration of rhG-CSF in normal donors, including serial assessment of serum rhG-CSF levels during rhG-CSF administration.
Materials and methods

Normal donors
Thirty healthy allograft donors were enrolled in this prospective, randomized study. The median age and sex of the c.i.v. and s.c. group were well balanced at 36 and 39 (16-61) years respectively. Written informed consent was obtained from all donors as approved by the institutional review board of the Ewha Women's University Medical Center. All donors were normal on physical examination, routine hematological and biochemical screening.
Mobilization and Collection of PBPC
For the c.i.v. group rhG-CSF (Filgrastim, Kirin Brewery Co, Tokyo, Japan), 10 mg/kg/day was administered for six consecutive days by continuous 24-h intravenous infusion to inpatients. For the s.c. group, 10 mg/kg of rhG-CSF was administered s.c. every 24 h for 6 days. Since the previous study on s.c. administration of rhG-CSF, peripheral blood (PB) CD34 þ levels reached near maximum after 4 days (about 76 h from the start of rhG-CSF) of rhG-CSF treatment, 10 we collected PBPC on the day following the fourth dose (about 76-78 h from the start) of rhG-CSF in the s.c. group using a blood cell separator (COBE Spectra, Lakewood, CO, USA). Since in the previous study of c.i.v. administration of rhG-CSF, PB CD34 þ levels reached near maximum after 3-4 days of the rhG-CSF treatment, 9 we also collected PBPC after 4 days (74-76 h) from the start of rhG-CSF. rhG-CSF (either s.c. or c.i.v.) treatment was continued for 6 days, irrespective of PBPC yield. The total blood volume processed per apheresis was three times the donor's blood volume at flow rates of 70À80 ml/min. Whole blood: anticoagulant ratio was programmed and anticoagulant citrate dextrose solution (ACD-A) was used as an anticoagulant. Total CD34 þ cells collected were assayed according to the International Society of Hematotherapy and Graft Engineering (ISHAGE) guideline. 11 The target dose of CD34 þ cell/kg was a minimum of 4 Â 10 6 /kg of patients. Daily collection was performed to reach the target dose.
Immunophenotyping
For the measurement of complete blood counts and CD34 þ cell numbers, venous PB sampling was performed immediately before the administration of rhG-CSF (baseline) and 24, 48, 72, 96, 120, 144 h in both groups. PB mononuclear cells (MNC) were isolated by standard Ficoll-Hypaque (Amersham Biosciences, Uppsala, Sweden; density, 1.077 g/ml) density gradient centrifugation. Isolated cell preparations (1 Â 10 6 MNC) were incubated for 30 min at 41C in the dark with fluorescein isothiocyanate (FITC)-conjugated anti-CD34 (HPCA-2; Becton Dickinson, San Jose, CA, USA). As isotype controls for the staining, we used FITC-conjugated mouse immunoglobulin (Ig) G1. Phenotypic analysis of CD34 þ cells was performed with a FACS Calibur flow cytometer (Becton Dickinson) equipped with a 15-mW air-cooled argon-ion laser tuned at 488 nm. Cell Quest software was used for data acquisition and analysis. The serum level of rhG-CSF in c.i.v. and s.c. group was monitored at basal level, 4, 8, 12 and 24 h then daily. Serum concentrations of rhG-CSF were determined by enzyme-linked immunosorbent assay (ELISA) with monoclonal anti-human rhG-CSF antibody using ELISA kit (Quantikine, R&A Systems, Minneapolis, MN, USA). The sensitivity of the analysis was 20 pg/ml.
Statistical analysis
Data are presented as mean7s.e.m. For statistical comparisons of values before and after rhG-CSF administration and comparison of values between groups, repeated measures of ANOVA were performed using SPSS for Windows (package 11.0). Mean serum rhG-CSF levels between two groups were compared in independent samples by the t-test. A significant difference was defined as a P-value of o0.05.
Results
Kinetics of CD34
þ cell mobilization /l, respectively. After c.i.v. of rhG-CSF, WBCs increased daily, peaking on day 4 and reaching approximately 6.4-fold above the baseline (Table 1) . Changes in MNC counts were similar to those found in WBC counts. The number of MNC increased 1.9-fold above the baseline on day 4, but no further increase occurred on day 5. Similar patterns of changes in WBC, granulocytes and lymphocytes were found after s.c. administration (Table 1) .
Although there were variations among the healthy donors, the statistical peak of CD34 þ cell levels in the c.i.v. arm was consistently observed on day 3. The percentage and absolute number of CD34 þ cells significantly increased on day 3 (0.9070.18%, 49.31710.47 Â 10 3 /ml), compared with baseline values (0.0970.04%, 1.887 0.24 Â 10 3 /ml). Up to the fifth day of rhG-CSF treatment, the circulating CD34 þ cell population remained at a plateau level and then decreased by the sixth day. In contrast, CD34 þ cells after s.c. administration were mobilized over a similar time course as published previously, reaching near maximum levels after 4 days of rhG-CSF treatment and peaking on day 5 (Table 1 ). There was a significant CD34 þ cell count difference from day 1 in both groups compared with the baseline level. Although there were no statistical differences in percentage of CD34 þ cells between c.i.v. and s.c. on day 3, absolute numbers of CD34 þ cells were higher in the c.i.v. group than the s.c. group (49.3 vs 35.9/ml, P ¼ 0.043). Table 2 shows the changes in rhG-CSF level at baseline and during mobilization after rhG-CSF administration. Peak levels were found at 8 h at the concentration of 15 414.672 908.9 pg/ml in c.i.v. group. The level then returned gradually to the base level. The peak serum rhG-CSF after s.c. administration was reached at 8 h at the concentration of 24 998.07580.6 pg/ml. Its level quickly declined by 24 h. The mean concentration of rhG-CSF in the s.c. group was higher up to 12 h than that of the c.i.v. group. The c.i.v. group level then remained higher than the s.c. group until day 5. The serum rhG-CSF level declined as the circulating WBC count increased (Figure 1) .
Changes in rhG-CSF level and PBPC collection
In 12 of 15 subjects in the c.i.v. group and in 11 of 15 subjects in the s.c. group, the target dose of X4 Â 10 
/kg
Comparison of IV vs SC G-CSF mobilization K-E Lee et al and 5.5870.75 Â 10 6 /kg in total, respectively, but there was no statistical difference (P ¼ 0.281). The most frequent side effects of rhG-CSF were mild bone pain, headache, fatigue and occasional nausea. These symptoms were similar in the c.i.v. and s.c. groups (data not shown) and they were relieved with acetaminophen. Increase in alkaline phosphatase and a mild decrease in platelet count occurred in both groups. These effects were transient and returned to normal within 2-3 weeks.
Discussion
The most commonly used schedule for rhG-CSF mobilization in normal individuals is rhG-CSF (10-12 mg/kg) s.c. either once a day or divided, twice per day. With the s.c. schedule, it takes 4-6 days to reach optimum mobilization. 12, 13 Using this schedule, male sex, young age (ie o38 or o40), rhG-CSF given twice daily(ie 5 mg/kg, bid), and a high rhG-CSF dose (ie 20-24 mg/kg) were reported, 2,4,5,12 as factors favoring increased mobilization, but other reports have failed to confirm these associations. 3, 12 In our Comparison of IV vs SC G-CSF mobilization K-E Lee et al randomized trial, administration of rhG-CSF by c.i.v. led to more rapid CD34 þ cell mobilization for 24-48 h. The reason for this observation is unclear. Several possible mechanisms for mobilization have been proposed. Administration of antibodies against VLA-4, vascular cell adhesion molecules-1 (VCAM-1) and AMD3100, a CXCR-4 antagonist results in mobilization of progenitors to the blood. [14] [15] [16] [17] Chemokines such as stromal derived factor-1 (SDF-1), as well as proteolytic enzymes such as various MMPs and neutrophil proteases are also involved in the mobilization process. [18] [19] [20] [21] [22] [23] We did not investigate whether any of the above factors may be affected by the route of rhG-CSF administration. The c.i.v. group had the higher serum rhG-CSF levels. The serum level of rhG-CSF, after the c.i.v. and s.c. administration, reached a peak level at 8 h and then decreased thereafter rather quickly, despite the daily administration of rhG-CSF. However, the serum level of rhG-CSF was maintained at a higher level in the c.i.v. group than the s.c. group after 24 h of rhG-CSF treatment ( Table 2 ). Peak mobilization of CD34 þ cells in the c.i.v. and s.c. groups occurred while the serum level of rhG-CSF was near base line. Watts et al also reported the lack of correlation between serum rhG-CSF concentration and peak progenitor counts. 6 Interestingly, a decrease in serum rhG-CSF concentration is associated with an increase in expression of the membrane rhG-CSF receptor gene. [24] [25] [26] In conclusion, we showed that the kinetics of CD34 þ mobilization can be affected by the mode of rhG-CSF administration. c.i.v. infusion of rhG-CSF resulted in more rapid CD34
þ cells mobilization when compared to s.c. injection, by 1-2 days. Despite the complexity of delivering c.i.v. G-CSF to normal donors, the large amount of CD34 þ cells which are collected via c.i.v. G-CSF within 3 days may be useful for the patients who are suffering severe pneumonia due to 'slow engraftment' or 'graft failure' after allogeneic bone marrow or PB progenitor cell transplantation. However, in most cases, s.c. G-CSF administration for allogeneic PBPC mobilization is likely to remain the standard approach.
